Biothera settles beta-glucan patent case

By Dominique Patton

- Last updated on GMT

Biothera, the maker of immune-boosting ingredients, says it has
settled a dispute over its beta-glucan patents with Californian
firm Cypress Systems.

According to Biothera, Cypress has agreed to stop selling yeast beta-glucan and has acknowledged the validity of Biothera's patents as part of the settlement of a lawsuit filed in federal district court last March.

The settlement "adds clarity to the market for beta-glucan products, provides Biothera with new sales and further strengthens our position in two pending patent infringement lawsuits"​, said Richard Mueller, Biothera president and chief executive officer.

Biothera sued Fresno-based Cypress for infringing patents that give it the exclusive right to make and sell yeast beta-glucan as a dietary supplement.

Biothera has also sued Norwegian company Biotec Pharmacon, which makes the immune health supplement Immutol, and the product's distributor, Immunocorp. A third lawsuit was filed against Fenchem Enterprises, a Chinese ingredient company.

In an interview earlier this year, Mueller said that patent infringements are the result of what has been, until recently, a very fragmented intellectual property landscape for the ingredient.

"Early on there were many people involved in the R&D of beta glucan and some of the patents overlap,"​ he told

The firm has through two acquisitions gained a large bulk of the intellectual property on the use of beta 1,3/1,6 glucan derived from Baker's yeast (Saccharomyces cervisiae) and its use in supplements.

Under the settlement with Cypress Systems, Biothera will gain the other firm's customer list and invoices for the past two years, its supplier invoices, and its "Beta Precise" trademark.

"We have already been in contact with many of Cypress Systems' customers and have begun to provide them with our BetaRight 3-6 or WGP 3-6 products,"​ said Mueller.

Related news

Related products

show more

Probiotic for Children’s Health: B. subtilis DE111

Probiotic for Children’s Health: B. subtilis DE111

Deerland Probiotics & Enzymes | 01-Apr-2021 | Technical / White Paper

In a 2020 survey parents said they see digestive supplements as allies in keeping their kids healthy physically and mentally in these uncertain times;...

First Low Dose Resistant Starch (RS2)

First Low Dose Resistant Starch (RS2)

Solnul™ | 24-Mar-2021 | Technical / White Paper

Clinically-proven at doses as low as 3.5 g, Solnul™ is the first low dose resistant starch, effective at 1/10 of the previously documented dosage.

New Levagen®+ PEA Study Shows Benefits for Sleep

New Levagen®+ PEA Study Shows Benefits for Sleep

Gencor | 17-Mar-2021 | Technical / White Paper

For most of us here in the United States, we sprang forward this weekend. In addition to the sun being out later, it also means our circadian clock has...

Related suppliers

Follow us


View more